Thymosin Alpha-1 10 mg

Technical Details

Dosage & Usage Guidelines

Establishing a precise Thymosin Alpha-1 dosage is critical for obtaining valid research data. As a potent research chemical, it is not intended for human consumption, and all studies must be designed with strict safety and ethical protocols. For the 10 mg vial from Dragon Pharma, researchers reconstitute the lyophilized powder with bacteriostatic water to achieve a precise concentration for subcutaneous administration.

Common research protocols are based on clinical studies and typically involve a dosage of 1.0 mg to 1.6 mg, administered two to three times per week. Some intensive protocols may initiate research with a "loading phase" of daily administration for 1-2 weeks before transitioning to the maintenance schedule of 2-3 times per week. The short half-life of approximately 2 hours is offset by its long-lasting effects on immune cell function, making frequent daily dosing unnecessary. Research should always commence at the lower end of the dosage spectrum to carefully monitor the subject's response.

Thymosin Alpha-1 Cycle

Designing an effective Thymosin Alpha-1 research cycle requires an understanding of its role as a modulator rather than an acute stimulant. Immune system optimization is a process, and cycles are therefore typically longer than those for other peptides. A standard research cycle can range from 4 to 8 weeks, with some protocols extending to 12 weeks for chronic conditions. Given its excellent safety profile in research models, longer cycles are feasible, often followed by a break of 4-6 weeks.

Thymosin Alpha-1 is highly synergistic when studied alongside other recovery and performance compounds. For comprehensive tissue repair and injury recovery, it is often stacked with BPC-157. To accelerate muscle recovery and reduce systemic inflammation, researchers frequently combine it with TB-500. During intense cutting phases where immune function can be compromised, adding a metabolic optimizer like Aicar 50 mg can provide valuable data. For those studying the effects of deep, restorative sleep on immunity and recovery, DSIP 10 mg is an excellent research companion. Finally, to support overall cellular health and combat oxidative stress during training, GHK-cu 50 mg can be incorporated into the observational protocol.

Possible Side Effects

Thymosin Alpha-1 is renowned in research for its exceptional safety profile and high tolerance. Because it works by modulating the body's own systems rather than introducing a foreign mechanism, side effects are rare and typically very mild when observed. The most commonly reported issue in some research models is minor discomfort, redness, or itching at the injection site, which is common with many subcutaneous peptides.

In very rare instances, if a subject has an underlying and undiagnosed autoimmune condition, there is a theoretical risk of exacerbating the condition due to the immunomodulatory action. However, in standard research models, this is not a common observation. There are no known cases of hepatotoxicity, renal toxicity, or hormonal imbalances associated with Thymosin Alpha-1. It does not cause water retention, high blood pressure, or any androgenic side effects. Its excellent tolerability is a key reason for its widespread research interest. This compound is strictly for controlled laboratory research and is not meant for human consumption.

Reconstitution and Research Protocol

Proper handling of Dragon Pharma Thymosin Alpha-1 is essential to preserve its bioactivity and ensure research integrity. The lyophilized powder must be stored in a refrigerated environment between 2°C and 8°C (36°F and 46°F) at all times, both before and after reconstitution. To prepare the peptide for research, it must be reconstituted gently with bacteriostatic water. The water should be injected slowly down the side of the vial, and the vial should be rolled gently between the palms until the solution is clear. Aggressive shaking should be avoided to prevent damaging the peptide's structure.

Given the multi-dose nature of the protocol, maintaining sterility is paramount. Once reconstituted, the solution remains stable for approximately 3-4 weeks when refrigerated. Researchers should mark the vial with the date of reconstitution and adhere to a strict aseptic technique every time a dose is drawn. Using alcohol swabs to clean the rubber stopper before each insertion is a standard best practice to prevent microbial contamination.

Research Applications and Synergies

The primary research application for Thymosin Alpha-1 in athletic models revolves around preventing the "open window" of immunosuppression that follows prolonged, intense exercise. During this period, athletes are more susceptible to upper respiratory tract infections. Research focuses on how Ta1 can shorten or close this window, ensuring consistent training. Beyond general immunity, its hepatoprotective properties make it a subject of interest for studies involving compounds that can stress the liver, and its role in enhancing vaccine response is a key area of immunological research.

Its synergy with other peptides is profound. When stacked with BPC-157 and TB-500, it creates a powerful "recovery trifecta," addressing immune function, local tissue repair, and systemic healing simultaneously. For researchers studying cognitive performance under stress, its potential anti-anxiety effects and synergy with nootropics like Selank are also of significant interest.

Shipping & Product Authenticity

What to Expect

• ✔ Orders are processed after payment confirmation
• ✔ USA Domestic shipping is typically faster when local stock is selected
• ✔ International orders include tracking, though update frequency may vary by destination
• ✔ Multiple warehouses may result in separate shipments when applicable

For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.

Storage

Store the lyophilized powder at controlled room temperature (15–25°C) in a dry, dark place, away from direct light and moisture. The unopened vial should be kept in its original packaging to maintain stability.

After reconstitution, store the solution at 2–8°C and use within 14 days. Do not freeze. Discard any unused portion after the recommended storage period. Before use, inspect the solution and avoid use if it appears cloudy, discolored, or contains particulate matter, or if the vial or seal is compromised.

Keep out of reach of children. Follow proper handling and sterile injection practices during research use.

Proper storage conditions help maintain product stability and consistent performance across the product's shelf life.

Frequently Asked Questions